[Allogeneic bone marrow transplantation in severe combined immune defects (SCID)].
Bone marrow transplantation (BMT) represents the therapy of choice in severe combined immunodeficiency (SCID). Besides a short description of the clinical picture and of the diagnostical criteria of the disorder, the basis and results of BMT in SCID are presented. This treatment can result in the complete immunological reconstitution with resulting cure of affected patients. Recently, the use of other than HLA-identical marrow donors has become possible, such as haploidentical parents. Threatening complications from graft versus host disease are preventable by depleting T-cells from marrow grafts. Early results of this new approach are very encouraging, and represent significant advance in clinical BMT.
D016026:Bone Marrow Transplantation; D002648:Child; D006086:Graft vs Host Disease / Q000517:prevention & control; D006087:Graft vs Host Reaction; D006680:HLA Antigens / Q000235:genetics; D006801:Humans; D007108:Immune Tolerance; D007153:Immunologic Deficiency Syndromes / Q000151:congenital* / Q000601:surgery; D013601:T-Lymphocytes / Q000276:immunology
D006680:HLA Antigens
Allogene Knochenmarktransplantation bei schweren kombinierten Immundefekten (SCID).